The Belfer Institute Mission
The mission of the Belfer Institute for Applied Cancer Science is to integrate academic, industry and clinical resources/expertise to enhance success in oncology drug discovery.
There are nearly 12 million people in the U.S. living with cancer and half of all men and one-third of all women in the U.S. will develop cancer in their lifetimes. While cancer therapies are improving and some cancers can now be treated effectively, there still remains a critical unmet medical need for safe and effective treatments. We believe that the next generation of cancer therapies will be identified out of emerging cancer genomics research and our goal is to help develop revolutionary new therapies that target specific molecular aberrations and attack cancer’s root causes.
In the News
Dr. Cloud Paweletz's publication - "Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA" - cited in Oncology Times "Best Lung Cancer Research of 2014".
Molecular Cancer Research (MCR) editorial group has selected a Belfer publication - “Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3” - to be reprinted in a 2014 Must-Read compilation for AACR.
Dr. P. Janne and Dr. C. Paweletz discuss an innovative approach for tumor genotyping and disease monitoring for targeted lung cancer therapies.
Belfer & Janssen announce collaboration on cancer immunotherapies for lung cancer
Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer
Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.